Results 91 to 100 of about 908,554 (203)

Molecular Diagnostics in Thyroid Nodules: Current Applications, Clinical Value, and Future Perspective

Med Research, EarlyView.
ABSTRACT Molecular diagnostics have become an important adjunct to ultrasonography and fine‐needle aspiration (FNA) for thyroid nodules, especially in Bethesda III/IV cytology where malignancy risk is uncertain. This narrative review summarizes the diagnostic and prognostic value of key genomic drivers (BRAF V600E, RAS, RET, TERT, and selected fusions)
Guohui Xiao, Min Ding, Zhixue Min, Yihan Dong, Xuanye Cao, Qiang Lu, Cong Chen, Yahui Wu, Xin Guo, Zhen Wu, Jing Xie, Dan Xu, Haizhen Chen, Rongli Xie, Jian Fei   +14 more
wiley   +1 more source

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. [PDF]

, 2019
Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer,
Carter, Jennifer L, Elkin, Sheryl K, Ikeda, Sadakatsu, Kurzrock, Razelle, Tomson, Brett N   +4 more
core  

Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. [PDF]

, 2020
Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors.
Al-Sarraj, S, Andreiuolo, F, Aquilina, K, Avery, A, Bailey, S, Baird, L, Baker, SJ, Bale, TA, Bloom, T, Boult, JKR, Brandal, P, Bridges, L, Burford, A, Cairns, C, Capper, D, Capra, M, Carai, A, Carceller, F, Carvalho, DM, Caspi, S, Chalker, J, Chandler, C, Clarke, M, Colafati, GS, Cowley, MJ, Crosier, S, Cryan, JB, Dalton, JD, Davare, MA, Dinjens, WNM, Diomedi-Camassei, F, Doey, LJ, Driever, PH, Dunkel, IJ, Ebinger, M, Ellison, DW, Faganel Kotnik, B, Fairchild, AR, Farrell, M, Gilheeney, SW, Haberler, C, Hargrave, DR, Hassall, TEG, Haupfear, K, Hettmer, S, Hiddingh, L, Howell, L, Hubank, M, Hughes, D, Ismer, B, Izquierdo, E, Jacques, TS, Jones, C, Jones, DTW, Karajannis, MA, Karremann, M, Kerl, K, Knipstein, J, Kordes, U, Korshunov, A, Kram, DE, Kramm, CM, Kristiansen, M, Kurian, KM, Lowis, SP, Macdonald, TJ, Mackay, A, Marshall, LV, Martin, AJ, Mastronuzzi, A, Maybury, M, Miele, E, Mitchell, C, Molinari, V, Moore, AS, Natrajan, R, Newman, S, Ng, H-K, Olsen, TK, Orisme, W, Packer, R, Pfister, SM, Pickles, JC, Pietsch, T, Popov, S, Popović, M, Preusser, M, Proszek, PZ, Robinson, SP, Rosenblum, MK, Rowe, C, Sahm, F, Schittenhelm, J, Schuhmann, MU, Schüller, U, Sill, M, Slavc, I, Snuderl, M, Solomon, DA, Stoler, I, Sturm, D, Tatevossian, RG, Temelso, S, Tsoli, M, Vinci, M, Virasami, A, von Deimling, A, Wen, J, Witt, O, Wood, MD, Worst, BC, Zebian, B, Ziegler, DS, Zuckermann, M   +113 more
core   +2 more sources

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples

Cytopathology, EarlyView.
The study evaluates the use of residual liquid‐based cytology (LBC) samples from pancreatic ductal adenocarcinoma (PDAC) for molecular analysis. It shows that LBC samples preserve nucleic acid quality and remain suitable for next‐generation sequencing (NGS) and MSI testing even after prolonged storage, underscoring their value when other samples are ...
Raquel Antón‐Peñalver, María Ortega, Jose Francisco González‐Muñoz, Desamparados Compañ, Constanza Galindo, Clara Arnau, Marisol Huerta, Valentina Gambardella, Desamparados Roda, Rosana Villagrasa, Vicente Sanchiz, Andrés Peña, Elena Muñoz‐Forner, Isabel Mora Oliver, Luis Sabater, Andrés Cervantes, Antonio Ferrández, Clara Alfaro‐Cervelló   +17 more
wiley   +1 more source

Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan

Cancer Medicine
Background Members of the neurotrophic tropomyosin receptor kinase (NTRK) gene family, NTRK1, NTRK2, and NTRK3 encode TRK receptor tyrosine kinases. Intra‐ or inter‐chromosomal gene rearrangements produce NTRK gene fusions encoding fusion proteins which ...
Eiji Nakata, Tatsunori Osone, Toru Ogawa, Tomoyuki Taguchi, Kana Hattori, Shinji Kohsaka   +5 more
doaj   +1 more source

Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

Scientific Reports, 2023
NTRK gene fusions are rare somatic mutations found across cancer types with promising targeted therapies emerging. Healthcare systems face significant challenges in integrating these treatments, with uncertainty in prevalence and optimal testing methods ...
Sophie O’Haire, Fanny Franchini, Yoon-Jung Kang, Julia Steinberg, Karen Canfell, Jayesh Desai, Stephen Fox, Maarten IJzerman   +7 more
doaj   +1 more source

Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA):a molecularly distinct brain tumor type with recurrent NTRK gene fusions [PDF]

, 2023
Glioneuronal tumors are a heterogenous group of CNS neoplasms that can be challenging to accurately diagnose. Molecular methods are highly useful in classifying these tumors—distinguishing precise classes from their histological mimics and identifying ...
Abdullaev, Zied, Aldape, Kenneth, Alexandrescu, Sanda, Banan, Rouzbeh, Blume, Christina, Bogumil, Henri, Boldt, Henning B., Boué, Daniel R., Brandner, Sebastian, Cherkezov, Asan, Deckert, Martina, Ecker, Jonas, Frank, Stephan, Friedel, Dennis, Goldbrunner, Roland, Haberler, Christine, Hench, Jürgen, Herold-Mende, Christel, Hinz, Felix, Ismer, Britta, Jones, David T.W., Korshunov, Andrey, Kristensen, Bjarne Winther, Kurth, Ina, Melchior, Linea C., Milde, Till, Ng, Ho Keung, Olesen, Viola, Pajtler, Kristian W., Pfister, Stefan M., Rahmanzade, Ramin, Reuss, David E., Sahm, Felix, Satgunaseelan, Laveniya, Scheie, David, Schittenhelm, Jens, Schrimpf, Daniel, Sehested, Astrid, Seidlitz, Annekatrin, Selt, Florian, Shi, Zhi Feng, Sievers, Philipp, Sill, Martin, Snuderl, Matija, Tauziède-Espariat, Arnault, Timmer, Marco, Unterberg, Andreas, Varlet, Pascale, von Deimling, Andreas, White, Christine L., Wick, Wolfgang, Witt, Olaf   +51 more
core   +1 more source

Molecular pathology of phyllodes tumours of the breast—much more than MED12

Histopathology, EarlyView.
Phyllodes tumours can develop from fibroadenomas bearing MED12 variants by the development of pTERT alterations (“MED12 pathway”) or de novo (“MED12 independent pathway”). Grade progression is associated with increasing genetic complexity including cancer driver gene aberrations. Molecular alterations can be useful in assigning grade and distinguishing
Jia‐Min B Pang, Kylie L Gorringe, Puay Hoon Tan, Stephen B Fox   +3 more
wiley   +1 more source

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach [PDF]

, 2018
Background: TRK fusion cancer results from gene fusions involving NTRK1, NTRK2 or NTRK3. Larotrectinib, the first selective TRK inhibitor, has demonstrated an overall response rate (ORR) of 75% with a favorable safety profile in the first 55 ...
Albert, C. M., Berlin, J. D., Bielack, S. S., Cox, M. C., Cruickshank, S., Doz, F., Drilon, A., Dubois, S. G., Federman, N., Geoerger, B., Hong, D. S., Ku, N. C., Kummar, S., Lassen, U. N., Mascarenhas, L., McDermott, R., Oh, D. Y., Schilder, R. J., Tan, D. S., van Tilburg, C. M.   +19 more
core   +1 more source